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Introduction
Molecular recognition in biological systems relies on the
existence of specific attractive interactions between two part-
ner molecules. Structure-based drug design seeks to identify
and optimizesuchinteractionsbetweenligandsandtheir host
molecules, typically proteins, given their three-dimensional
structures. This optimization process requires knowledge
about interaction geometries and approximate affinity con-
tributions of attractive interactions that can be gleaned from
crystal structure and associated affinity data.
Here we compile and review the literature on molecular
interactions as it pertains to medicinal chemistry through a
combinationofcareful statisticalanalysisofthe largebodyof
publicly available X-ray structure data and experimental and
theoretical studies of specific model systems. We attempt to
extract key messages of practical value and complement
references with our own searches of the CSD
a,1 and PDB
databases.
2Thefocusisondirectcontactsbetweenligandand
protein functional groups, and we restrict ourselves to those
interactions that are most frequent in medicinal chemistry
applications. Examples from supramolecular chemistry and
quantummechanicalormolecularmechanicscalculationsare
cited where they illustrate a specific point. The application of
automated design processes is not covered nor is design of
physicochemical properties of molecules such as permeability
or solubility.
Throughout this article, we wish to raise the readers’
awareness that formulating rules for molecular interactions
isonlypossiblewithincertainboundaries.Thecombinationof
3Dstructureanalysiswithbindingfreeenergiesdoesnotyield
a complete understanding of the energetic contributions of
individualinteractions.Thereasonsforthisarewidelyknown
but not always fully appreciated. While it would be desirable
to associate observed interactions with energy terms, we have
to accept that molecular interactions behave in a highly
nonadditive fashion.
3,4 The same interaction may be worth
differentamountsoffreeenergyindifferentcontexts,andit is
very hard to find an objective frame of reference for an
interaction, since any change of a molecular structure will
have multiple effects. One can easily fall victim to confirma-
tion bias, focusing on what one has observed before and
building causal relationships on too few observations. In
reality, the multiplicity of interactions present in a single
protein-ligand complex is a compromise of attractive and
repulsive interactions that is almost impossible to deconvo-
lute.Byfocusingonobservedinteractions,oneneglectsalarge
partofthethermodynamiccyclerepresentedbyabindingfree
energy: solvation processes, long-range interactions, confor-
mational changes. Also, crystal structure coordinates give
misleadingly static views of interactions. In reality a macro-
molecular complex is not characterized by a single structure
but by an ensemble of structures. Changes in the degrees of
freedomofbothpartnersduringthebindingeventhavealarge
impact on binding free energy.
The text is organized in the followingway. The first section
treats general aspects of molecular design: enthalpic and
entropic components of bindingfree energy,flexibility, solva-
tion, and the treatment of individual water molecules, as
well as repulsive interactions. The second half of the article
is devoted to specific types of interactions, beginning with
hydrogenbonds,movingontoweakerpolarinteractions,and
ending with lipophilic interactions between aliphatic and
aromatic systems. We show many examples of structure-
activity relationships; these are meant as helpful illustrations
but individually can never confirm a rule.
General Design Aspects
Entropic and Enthalpic Components of Binding. Like any
other spontaneous process, a noncovalent binding event
takes place only when it is associated with a negative bind-
ing free energy (ΔG), which is the well-known sum of an
enthalpicterm(ΔH) andanentropicterm(-TΔS).Theseterms
may be of equal or opposite sign and thus lead to various
thermodynamic signatures of a binding event, ranging from
exothermic to entropy-driven. An increasing body of data
from isothermal titration calorimetry (ITC) is available on
the thermodynamic profiles for many complexes.
5,6 Where
crystal structure information exists as well, it is tempting to
speculate about the link between thermodynamics and geo-
metry of protein-ligand complexes. A rough correlation
between the burial of apolar surface area and free energy
could be derived,
5 but beyond that, practically useful rela-
tionships between structure and the components of free
energy have remained elusive. This is not surprising, as both
entropy and enthalpy terms obtained from calorimetric
experiments contain solute and solvent contributions and
thus cannot be interpreted on the basis of structural data
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alone. The direct experimental estimation of solvent effects
has been attempted
7 but always requires additional assump-
tions.Onlytheoreticaltreatmentsallowaseparationofthese
effects.
8 Thus, computer modeling can support the interpre-
tation of experimental observations.
Furthermore, from an experimental point of view, such
studies are very demanding: Error margins are significantly
largerthanthefittingerrorsusuallyreported
9anddependon
subtle details of experimental setup.
10 Entropy and enthalpy
values are sensitive to conditions such as salt concentrations
and choice of buffer. Protonation and deprotonation steps
associatedwiththebindingneedtobeunderstoodindetail,
11
assignificantdifferencesinprotonationstatescanoccureven
within congeneric series of ligands.
12
Freire suggested that best-in-class drugs bind to their
targets in an enthalpy-driven fashion.
13 His group estab-
lished a comprehensive ITC data set on HIV protease
inhibitors, concluding that second- and third-generation
inhibitors bind through a strong enthalpy component. One
may argue that this could be caused by a higher number of
specific backbone interactions, partially replacing the larger
lipophilic surface area of the first generation inhibitors, and
thatthelargerrelianceonbackboneinteractionscouldbethe
cause for the broader coverage of HIV protease mutants.
Still,eveninthisdatasetsmallstructuralchangescauselarge
difference in relative ΔH and TΔS contributions that are
hard to explain structurally. Amprenavir and darunavir
differ only in one cyclic ether moiety, but there is a drastic
difference of about 10 kcal/mol in binding enthalpy between
these two ligands.
14
Since entropic and enthalpic components of binding are
highly dependent on many system-specific properties, the
practitioner has to conclude that optimizing for free energy
is still the only viable approach to structure-based design.
Perhaps the greatest advantage in the attempt to interpret
components of ΔG is that it forces us to think about
two fundamental topics in unprecedented detail: viewing
protein-ligand complexes as flexible entities rather than
fixed structures and the role of desolvation effects. These
two topics will be discussed next.
Flexibility and Cooperativity. A discussion of the thermo-
dynamicsofligandbindingisnotcompletewithoutmention-
ing the phenomenon of entropy-enthalpy compensation.
The validity and generality of this phenomenon have been a
contentious topicfor many years. There is ample evidenceof
meaningless and spurious correlations between ΔH and
TΔS, often due to far larger variations (sometimes through
larger experimental errors) in ΔH than in ΔG.
15,16 Also,
compensation is no thermodynamic requirement:
17,18 If
changes in ΔH were always compensated by opposing
changes in TΔS, optimization of binding affinities would
hardly be possible.
Nevertheless, there seems to be a mechanism behind the
compensation frequently observed
19 in host-guest chemis-
try
20 and in protein-ligand interactions.
21 In short, the
tighterandmoredirectedaninteraction,thelessentropically
favorable it is. Bonding opposes motion, and motion op-
poses bonding.
22 However, the detailed nature of these
compensatory mechanisms is highly system-dependent and
the mechanisms do not obey a single functional form. As a
consequence, noncovalent interactions can be positively co-
operative; that is, the binding energy associated with their
acting together is greater than the sum of the individual
binding free energies. Detailed studies by Williams on glyco-
peptideantibioticsindicatethatcooperativitymaybecaused
by structural tightening upon introduction of additional
interactions; interaction distances become shorter and
enthalpically more favorable. Evidence for such effects also
exists in protein-protein
23 and protein-ligand complexes.
Streptavidin becomes better packed upon binding to biotin
as evident from structural, mass spectrometry, and deuter-
ium exchange NMR experiments.
24 Hunter has proposed an
alternative model ofcooperativity.
25Flexiblemolecules may
exist in a series of partially bound states, where not all
Figure 1. Cooperativityofhydrogenbondformationandhydrophobiccontactsinasetofthrombininhibitors.Extensionofthelipophilicside
chainaloneincreasesaffinityby2.1kcal/mol.Additionoftheaminogroupincreasesaffinityby1.2kcal/mol.Cooperativitythereforeamounts
to 4.3 - 2.1 - 1.2 = 1.0 kcal/mol. Data from refs 30 and 31 were converted to kcal/mol and rounded to 1 decimal place.Perspective Journal of Medicinal Chemistry, 2010, Vol. 53, No. 14 5063
interactionsaremadeatthesametime.Uponintroductionof
furtherinteractions,thebalanceshiftstowardmorefrequent
formation of the interactions and less mobility. There is
experimental evidence for both the structural tightening
model
26andthemodelofpartiallyboundstates
27indifferent
systems. Since proteins bind ligands in many geometric
arrangements ranging from loosely surface-bound to deeply
buried, it is likely that both are valid in different contexts.
Ligands with increasingly longer linear and lipophilic side
chains have been observed to bind with increasingly favor-
able entropies and increasingly unfavorable enthalpies
against trypsin
28 and carbonic anhydrase.
29 Longer side
chains retain more residual mobility and form less tight (or
less frequent) interactions with the protein surface, trading
enthalpy for entropy.
In an impressively comprehensive study on several series
of thrombin inhibitors, the Klebe group has analyzed the
sources ofcooperativity between a lipophilic interaction and
a hydrogen bond.
30,31 The findings from this study can be
summarized as follows: (i) In the presence of the amino
substituent forming a hydrogen bond to the backbone of
Gly216, the gain in binding free energy of a given P3
substituent is significantly larger. This is illustrated by the
double functional group replacement cycle in Figure 1. (ii)
BothB-factoranalysesandMDstudiesconfirmadecreasein
residual motion of the P3 substituent in the presence of the
hydrogen bond. MD studies also indicate that the average
hydrogen bond distance is shorter with a P3 substituent
attached. (iii) In accordance with this finding, the introduc-
tionofthehydrogenbondmakesbondingsignificantlymore
exothermic, but the gain in enthalpy is largely compensated
by an entropic disadvantage.
What can we learn from this study? First, small changes in
ΔG often mask large and mutually compensating changes in
ΔH and TΔS. Focusing on ΔG in designing new molecules is
certainlystillthesafestbet.Second,inmedicinalchemistrywe
often rely on cooperative effects without even noticing, and
yet in our minds we attempt to decompose binding free
energies into additive elements. There is nothing wrong with
this empirical approach as long as we keep in mind that it is
primarily useful toteach usaboutthe limits of additivity. The
knowledge that specific interactions, in particular strongly
directed ones like hydrogen bonds, rigidify a protein-ligand
complex may help us to exploit cooperativity in a more
rational fashion. The Klebe data should also make us think
about the degree of mobility required in interactions with
different parts of the protein. Flexible domains may require
more flexible ligand moieties than highly ordered ones. The
thermodynamicsignatureofa“good”ligandisnotnecessarily
dominated by an enthalpic term. Our traditional focus on
visible interactions and on the induced fit model has led to an
overly enthalpicview ofthe world that neglectsflexibilityand
cooperativity. It also neglects local solvation phenomena,
whose details strongly affect the thermodynamic profile of a
molecular recognition event. We should learn to incorporate
these into our thinking, at least in a qualitative fashion.
Desolvation and the Hydrophobic Effect. The classic con-
cept of the hydrophobic effect is as follows: A hydrophobic
solute disrupts the structure of bulk water and decreases
entropy because of stronger bonding and ordering of water
molecules around the solute. Such disruptions can be mini-
mized if nonpolar solute molecules aggregate. Water then
forms one larger “cage” structure around the combined
solutes,whosesurfaceareawillbesmallerthanthecombined
surface areas of isolated solutes. This maximizes the amount
of free water and thus the entropy.
Ifthismechanismwerethesoledrivingforceforaprotein-
ligand interaction, all binding events involving hydrophobic
partnerswouldbeentropy-driven.Butspectroscopicevidence
indicates that hydrogen bonds at hydrophobic surfaces are
weaker
32 and water molecules more flexible
33 than originally
assumed. In addition, already simple water models show that
size and surface curvature of solutes have a dramatic impact
on their solvation thermodynamics.
34 Complexation thermo-
dynamics driven by enthalpic forces have been regularly
observed in host-guest chemistry and have been dubbed the
“nonclassical hydrophobic effect”.
35 Homans has carefully
studied the ligand-binding thermodynamics of the mouse
major urinary protein (MUP). The key to the extremely
favorable enthalpy of binding of ligands to MUP seems to
be the suboptimal hydration of the binding pocket in the
unbound state.
36 The negative change in heat capacity upon
binding,ahallmarkofthehydrophobiceffect,isalsoobserved
withMUPligands. It islargely determined by ligand desolva-
tion, with minor contribution from desolvation of the pro-
tein.
37 Similar observations have been made for hydrophobic
cavities in other proteins.
38 It is quite likely that the synthetic
hosts displaying an enthalpy-driven complexation behavior
are also incompletely hydrated in the unbound state because
they typically feature narrow lipophilic clefts not unlike that
of MUP (see ref 39 for a recent example). Desolvation costs
are also the likely cause why some ligands that seem to fit
into a binding site cannot experimentally be confirmed to be
inhibitors. An ITC study on the interactions between simple
benzamidines and trypsin concludes that the unfavorable
desolvation of the oxyanion hole area upon binding of
p-tert-butylbenzamidinium causesthe observed complete loss
of binding affinity for this molecule.
28
Figure 2. Binding mode of a factor Xa inhibitor from GSK.
40 The
depictedcompound(PDBcode2j4i)hasaKiof1nM.Replacingthe
isopropylgroup(marked in red)byhydrogen reduces theaffinity to
39 μM.5064 Journal of Medicinal Chemistry, 2010, Vol. 53, No. 14 Bissantz et al.
From these studies it becomes clear that carefully probing
the hydration state of a protein binding pocket in the un-
bound state should be a standard element of structure-based
design, as it will likely point out regions where most binding
energy can be gained. Failure to match key hydrophobic
areas with appropriate ligand moieties can have a severe
impactonbindingaffinity.Figure2showsthatanoptimized
factor Xa inhibitor is rendered virtually inactive when the
key interacting group in the S4 pocket is replaced by hydro-
gen.
40 Not only does the isopropyl group optimally interact
with the S4 pocket (see Hydrophobic Interactions) but its
removal leads to a very unfavorably solvated state of the
pocket
41,42thatislikelythemainreasonforthedramaticloss
of affinity.
Structural Water. Any ligand binding event displaces
water molecules from the binding site. In structure-based
design, most of these are never explicitly considered because
they are highly disordered and therefore rarely crystallogra-
phically observed.
43 Enzyme binding sites are in fact char-
acterized by easily displaceable water, as shown by Ringe in
her seminal work on transferring protein crystals to organic
solvents.
44 Those water molecules that are observed need to
be carefully analyzed; they might be replaceable or they
might be considered as part of the protein structure.
45
Analyses of high-resolution crystal structures by Poornima
and Dean showed that protein-ligand contacts are often
mediated by water molecules situated in deep grooves in the
bindingsiteandformingmultiple hydrogenbondswithboth
binding partners.
46 Relibaseþ, a database and query system
for analyzing protein-ligand complexes, contains a module
that allows a rigorous assessment of water structure in
binding sites.
47
The release of a water molecule from a rigid environment
should be entropically favorable. In a classic contribution,
Dunitz has estimated the upper limit of the entropy gain for
transferring a water molecule from a protein to water to be
2 kcal/mol at room temperature.
48 To reach the 2 kcal/mol
limit, a water molecule will have to be very tightly bound in
a rigid protein structure. The entropy gain in releasing the
water molecule will then be offset by a loss in enthalpy,
and conversely, less tightly bound water molecules might
approach or even exceed the entropy in bulk water. It has
been observed that even rather tightly bound water mole-
culescanretainaveryhighamountofresidualmobility.
49,50
Furthermore, protein flexibility may be significantly af-
fected by water binding. Cases are known where proteins
become more rigid
51 or more flexible
52 upon water bind-
ing. So how should one assess which water molecules are
replaceable?
Various flavors of molecular dynamics and free energy
calculations have been applied to study this problem. Essex
et al., using thermodynamic integration calculations in Monte
Carlo simulations, found that the calculated binding free
energies for individual water molecules allowed a rough
classification into those displaced by ligands and those
conserved across protein-ligand complexes; the conserved
ones are more tightly bound.
53 Li and Lazaridis computed
the thermodynamics of water displacement in concanavalin
A-carbohydrate complexes and concluded that “the final
outcome of water displacement is sensitive to the details of
the binding site and cannot be predicted by simple empirical
rules”. The complexity of the contributions of specific water
molecules to ligand binding has recently been re-emphasized
in a comprehensive study by Jorgensen et al.
54
Extensive computer simulations are not generally feasible
in a fast-paced drug discovery environment, but simple
geometric parameters describing the immediate protein
environment of a crystallographic water molecule can serve
as a useful guide to estimate whether it is displaceable by a
ligandmoiety.
55Inourhands,asimplegeometricrankfunction
based on the distances and angles of neighboring donor and
acceptor atoms in the protein, developed by Kellogg and
co-workers, has served as a practically useful metric.
56 Water
molecules with high ranks should be regarded as part of the
binding site.
57,58 These experience three or more hydrogen
bonds with the local environment and are usually located in
buriedpolarcavities.Replacementofanoptimallycoordinated
water molecule will require very high design precision because
otherwisetheenthalpylossmightbehardtoregain.Incontrast,
displaceable water molecules often participate in a water net-
workwithouttightbindingtotheprotein.More“sloppiness”in
the design is allowed in these cases.
A number of studies allow a direct comparison between a
ligandbindingtoastructuralwaterandaverycloseanalogue
displacing it. A nitrile substituent has successfully been used
as an isostere of a water hydrogen-bonded to a pyridine-like
acceptor nitrogen in EGFR kinase
59 and p38 MAP kinase
inhibitors
60 as well as in inhibitors of scytalone dehydra-
tase.
61 In all of these cases affinity was retained or even
improved. In peptide inhibitors of iNOS,
62 an amide and an
amine functionality were independently replaced by the
respective aminoxides and yielded equipotent inhibitors
replacing a water molecule bound by the heme carboxylates.
In all of these cases no more than two hydrogen bonds are
formed between protein and water, indicating nonideal
coordination. Campiani et al. reported an instructive coun-
terexample. They attempted to replace a water molecule
in acetylcholinesterase by derivatives of huperzine and
observed a dramatic loss in affinity.
63 The designed phenol
ligands clearly would not reach the position of the water,
Figure 3. Overlay of representatives of 15 different PDE10 inhibi-
torclasses.Twowatermoleculesaredeeplyburiedinthebindingsite
of the apo form and are hydrogen-bonded to two (left) and three
(right) protein residues, respectively. Only the less tightly bound
water molecule has been displaced by PDE10 inhibitors so far.Perspective Journal of Medicinal Chemistry, 2010, Vol. 53, No. 14 5065
which in addition is firmly coordinated by three hydrogen
bonds to the protein.
The binding site of PDE10 contains two buried water
molecules that are hydrogen-bonded to each other and to
two and three protein residues, respectively (Figure 3). This
high coordination suggests a large enthalpic penalty for the
removal of any of these. We found that the water molecule
with almost ideal tetrahedral coordination has not been
displaced byany known PDE10 ligand, while 1 outof 15dif-
ferent inhibitorserieswas abletoexpel thelesstightly bound
water molecule.
Wherever possible, a comparison between water place-
ments in multiple independently solved crystal structures
should be made to minimize errors during the modeling of
water sites in the refinement process.
64 Strongly bound
watermoleculesareoftenconservedacrossmultiplecrystal
structures. Alternatively, water sites have been predicted
computationally through MD simulations
65 or empirical
functionals.
41 An increasingly important area of investiga-
tion is the analysis of entire water clusters. Understanding
thehydrationpropertiesofsubpocketswithinbindingsites
can be the key to understanding ligand binding, as exem-
plified by research on the OppA protein.
66,67 Crystal
structures of complexes between OppA and peptides of
the general structure Lys-X-Lys reveal that certain water
molecules adopt the same position independently of the
nature of residue X. The strength of the interactions
betweenthesewatermoleculescanhelpexplainthebinding
affinities of the OppA-peptide complexes. tRNA-guanine
transglycosylase is another protein in which a conserved
water cluster has been carefully studied.
68,69 Achieving a
more general understanding of the properties of water
clusters is a challenge for the future. For example, ring-
shaped water clusters seem to be prominent in outer
hydration spheres
70 and perhaps in purely hydrophobic
binding pockets,
71 as they benefit from cooperativity of
their hydrogen bonds.
72
Repulsive Interactions. An important element of the
design process is the analysis of repulsive interactions one
may haveartificially generated upon modifying experimentally
determined coordinates of a complex in silico. This is even
morecriticalifpartoftheproteinistreatedasflexibleduring
a minimization step, since locally introduced strain can be
absorbed by other parts of the structure and can be dis-
sipated to such an extent that it becomes unrecognizable. It
is therefore advisible to keep the protein rigid with the
exception of only those parts that are known to adapt to
ligands or to create alternative hypothetical low-energy
states of a protein that are then kept fixed in the design
process. The availability of multiple crystal structures of the
same protein with different ligands is most useful here, as
their overlays allow the identification of backbone move-
ments and flexible side chains. Severe repulsive interactions
are not observed in nature, so distances significantly below
theshortestexperimentallyobservedonesaretobeavoided.
General steric fit can be assessed through surface depictions
of both binding partners. In addition, one may rely on
general molecular mechanics terms or simple van der Waals
distance criteria to analyze steric clashes. Conformations
should be carefully checked; force field minimization often
has the effect of achieving a good interaction at the expense
of a strained torsion angle. Torsion angles are the softest
conformation parameters and yet have the largest effects on
geometry.
73
Specific Intermolecular Interactions
Hydrogen bonds are by far the most important specific
interactions in biological recognition processes. Geometries
of hydrogen bonds follow strict rules, which were among the
first to be extracted from crystal structure databases. Interac-
tions between NH and carbonyl groups,
74 interactions of
hydroxyl groups with carbonyl, ether, and ester groups,
75
and hydrogen bonds to aromatic heterocycles
76 were studied
in detail. Systems like Isostar
77 and Superstar
78 have proven
usefulforvisualizingsuchinteractionpreferences.Thespatial
distribution of intermolecular contacts between carbonyl
groups and NH donors has been converted to energy maps,
highlightingcommonalities anddifferences betweenester and
amide acceptors.
79 This approach has also been applied to
protein structures, where goodagreementwas found between
statistical analysis and quantum mechanical calculations.
80
Here we will not exhaustively cover the topic of hydrogen
bonding but will present key facts and concepts.
Frequency distributions of classical hydrogen bond dis-
tances give rise to sharp peaks, allowing one to distinguish
small differences in median distances. In the CSD, hydrogen
bonds between amide CdO and OH have a median distance
of 2.75 A ˚ . With NH donors, the median distance increases to
about2.9A ˚ .WithinbindingsiteregionsofthePDB,thesame
median distances are observed. PDB distributions are signifi-
cantly broader but still clearly separated from each other
(Figure4).Intheory,thismeansthatahydrogenbondshould
bewithinabout(0.1A ˚ ofitsmedianobserveddistance.Ifthis
cannot be achieved in a relaxed state, the design should be
modified.Inpractice,however,suchrigiddistancecriteriacan
rarelybeapplied,sincetheadaptationofproteinstructuretoa
modified ligand is hard to predict. Furthermore, the coordi-
nateprecisionofproteinstructuresismuchlowerthanthatof
small molecule crystal structures, and it varies considerably
not only as a function of overall resolution.
81,82
We have analyzed the preferred geometries of a variety of
acceptorsand donorsbysearches in the CSD (see Figures S-1
and S-2 of Supporting Information). Even for the weakest
acceptors (ether, sulfonamide), the median distance is shorter
thanthesumofvanderWaalsradiiofthedonorandacceptor
heavy atom. Charged hydrogen bonds are considerably
shorter than comparable uncharged ones. For example, the
saltbridgebetweencarboxylateandammoniumhasamedian
Figure 4. Box plots (box region corresponding to the central 50%
of the distribution, dotted lines extending to max 1.5 times this
interval)ofhydrogenbondlengthdistributionswithNHandOHas
donors: (left) CSD statistics; (right) PDB statistics. In the PDB, the
distributions around roughly the same mean are significantly
broader.5066 Journal of Medicinal Chemistry, 2010, Vol. 53, No. 14 Bissantz et al.
distanceof2.79A ˚ .Withaneutralamineasacounterpart,this
distanceincreasesto2.83A ˚ .Ahydrogenbondbetweenamide
carbonyl and amine is typically 2.9 A ˚ long.
The angular preferences of hydrogen bonds are also quite
pronounced. A number of typical geometries are shown in
Figure5.Theangledonor-hydrogen333ac c e pt o ri sge ne ra ll y
above 150. Only ethers, which are rather weak acceptors,
show a somewhat higher variability of this angle. Hydrogen
bonds are generally formed along the direction of the free
electronpairoftheacceptoratom.Forexample,thepreferred
angle CdO333H has its peak at 120, corresponding to the
lone pair direction of the carbonyl oxygen. This mnemonic
ruledoesnotholdforsulfonylgroups,wherehydrogenbonds
along the SdO axis are slightly preferred. For sulfonyl and
carboxylate groups, one needs to further distinguish between
syn and anti directions with respect to the second oxygen
atom. Thesyn orientation is preferred over anti inbothcases.
The interaction with the syn lone pair is almost always an
asymmetriconewiththedonoratominteractingwithonlyone
of the oxygen atoms.
83 The last geometric feature to be
monitored is the deviation of the hydrogen bond from the
acceptor plane in the case of acceptors comprising π systems
(aromatic ring plane or the plane formed by carbonyl and its
twosubstituentatoms).Thedeviationfromtheacceptorplane
is generally below 25-30.
Whilethepreferredgeometriesofhydrogenbondsareeasily
defined, their contribution to affinity is highly context-
dependent. Davis and Teague,
84 Kubinyi,
85 and Ladbury
86
have collected many illustrative examples. Hydrogen bonds
always convey specificity to a recognition process but do not
always add much binding free energy. Desolvation of the
donor and the acceptor must occur for the hydrogen bond to
form, such that the effects of hydration and hydrogen bond
formation nearly cancel out.
87
Thus, a primary question in molecular design should be
which donors and acceptors need to be satisfied and not how
more hydrogen bonds can be formed. Analyses of entire
proteinstructuresshowedthatbothNHandCOgroupsform
hydrogen bonds to a very large percentage,
88 in particular in
highresolutioncrystalstructures,andtheremainingcasescan
usually be explained by artifacts of the crystal structures
or inadequacies of the search methods.
89 The number of
observed hydrogen bonds clearly increases with decreasing
solvent accessibility.
90 There is evidence, however, that not
satisfying a hydrogen bond donor in a protein, i.e., burying a
donor in a desolvated state, has more drastic energetic con-
sequencesthannotsatisfyinganacceptor.Homasetal.report
apenaltyof4.3-5.3kcal/molforahydroxylgroupbindingin
a hydrophobic pocket, due to the cost of desolvation.
91
Relatively little loss of free energy is incurred upon removal
of a hydrogen bond to a backbone carbonyl group. Bartlett
andco-workers showedthatreplacementsof NHby amethy-
lene group hardly reduced the binding affinity of peptidomi-
metic thermolysin inhibitors, whereas the replacement of NH
by oxygen allowed a dramatic loss in affinity by 4 kcal/mol.
92
The binding of acylated tripeptides and their analogues to
vancomycin gives a similar picture: replacement of NH by
methylene leads to a loss of 1.5 kcal in binding free energy,
replacementbyoxygentoalossof4.1kcal/mol.
93Inaseriesof
Chk1inhibitors,areductioninbindingaffinityof1.4kcal/mol
was observed in changing a pyrrole to a furane ring where in
bothcasestheheteroatomspointtowardtheCys87 backbone
carbonyl group. As in the previous two examples, this loss of
affinity is probably mostly due to the introduction of a
repulsive O333O interaction rather than due to the removal
of the NH333O hydrogen bond.
94
Alookattheworldofkinaseinhibitorsconfirmsthistrend.
The vast majority of kinase inhibitors with any direct hinge
interactions form a hydrogen bond to the backbone NH
situated at the center of the hinge strand. Where this is not
the case, the backbone NH is usually solvated (see, for
example, PDB code 1zz2 and ref 95). We are aware of only
a single ligand where the backbone NH has no good counter-
part: 4,5,6,7-tetrabromobenzotriazole forms two halogen
bondstotheflankingbackbonecarbonylgroupsbutnodirect
interaction with the NH group (PDB code 1p5e). In contrast,
hinge binding ligands often leave one backbone carbonyl
group in a desolvated state without a compensatory interac-
tion. PDB entries 3blr and 3fmd may serve as examples.
So far, we have neglected the fact that hydrogen bonds can
vary quite considerably in their intrinsic strength. To a first
approximation, this might be justified because a stronger
hydrogen bond also implies higher desolvation costs, so the
net free energy gain of a stronger hydrogen bond might be
minimal. However, the wide variation of the free energy
changes associated with hydrogen bonds indicates that
this picture is too simplistic. Just like solvent accessibility,
the geometry of hydrogen bonds and the nature of neighbor-
ing atoms are key parameters determining this free energy
change;hydrogenbondstrengthsshouldbecarefullyassessed
as well.
Thepropensitiesofmanyfunctionalgroupstoformhydro-
gen bonds have been experimentally determined and tabu-
lated by Abraham
96 a n dm o r er e c e n t l yb yL a u r e n c ei n
the form of the pKBHX scale, details of which have been
reviewed in this journal.
97 Where experimental data are not
available, acceptor strengths can be obtained from quantum
chemical calculations.
98 Calculated acceptor strengths and
those derived from IR spectroscopy generally correlate well
with each other, indicating that the entropic component of
Figure 5. Schematic depiction of the most preferred geometries of
hydrogenbondinteractions with various types ofacceptors: (a) pyri-
dine nitrogen, (b) carbonyl oxygen, (c) carboxylic acid, (d) ether
oxygen, (e) sulfonyl group.Perspective Journal of Medicinal Chemistry, 2010, Vol. 53, No. 14 5067
hydrogen bond formation in water is relatively constant
across acceptors.
Whatcanbelearnedfrom suchparameters?First,acceptor
strengths are not directly related to proton basicities. The
most basic center in a molecule is not necessarily the best
acceptor. Anappreciation of acceptor strengths can thus lead
to a better understanding of desolvation effects and interac-
tion preferences, for example, of more complex heterocycles.
Second, although rarely reported, cases are known where
acceptor (or donor) strengths correlate with affinity, leading
toimportantinsightsintoSAR.
99,100Finally,thesevaluescan
help design molecules with better overall properties, for
example, by modulating the nature of solubilizing groups.
There is good general agreement between statistical like-
lihoodsofhydrogenbondformationintheCSDandacceptor
strengths. For example, nitrogen acceptors in aromatic hetero-
cycles are more frequently observed to form hydrogen bonds
in the CSD than oxygen acceptors,
101 in agreement with
pKBHX data.
Our CSD searches also indicate a qualitative agreement
between hydrogen bond frequencies and pKBHX acceptor
strengths, as shown by the data in Table 1 for acyclic oxygen
atoms as acceptors and for a selection of planar heterocycles.
For the CSD searches, very generic substructures have been
used, and so the results should be taken as a qualitative and
average property of each functional group. In addition to
the nature of the functional group, many factors influence
acceptor strength. For example, cyclic amides (lactams) and
cyclic ethers are significantly stronger acceptors than acyclic
ones. Electron-donating substituents at the aromatic rings
increase the acceptor strength, while electron-withdrawing
ones decrease it. Aromatic ethers such as anisole are weaker
acceptors than aliphatic ones. Because of its extremely low
propensity to form hydrogen bonds, diphenyl ether might
even be regarded as a bioisostere of diphenylmethane.
Only30%ofthesulfonesandsulfonamidesformhydrogen
bonds. This raises the question of which type of interaction
this functional group prefers. In the CSD, we find that about
80% of the SO2 groups are in proximity (3.3-3.9 A ˚ )t oa n
aliphatic carbon atom (in our queries we used any methylene
unit-CH2-asaprototypehydrophobicgroup).InthePDB,
39% of the ligand sulfonyl groups are found to form a
hydrogen bond with either a protein donor or a structural
water molecule, while 74% are located in or close to van der
Waalsdistance(3.3-3.9A ˚ ) toanaliphaticgroup.Notably,of
the sulfonyl groups situated in a hydrophobic environmentin
the PDB, only 36% are found to interact simultaneously as a
hydrogen bond acceptor but 79% of the hydrogen-bonded
sulfonyl groups are found to interact simultaneously with a
hydrophobic group. These findings clearly indicate a dual
character of the weakly polar sulfonyl groups as a hydrogen
bond acceptor and as a hydrophobic group. An example of
the types of hydrophobic environments that sulfonyl groups
arefoundinisgiveninFigure6,whichdepictsasectionofthe
binding site of the ligand CRA-27934 within the cathepsin S
cocrystalstructure(PDBcode2fra).Thesulfonylgroupforms
several van der Waals interactions with nonpolar atoms and
forms weak hydrogen bonds with CR-H donors. Further
illustrative PDB examples include complexes of FK506 bind-
ing protein (1j4h) and phenylethanolamine N-methyltrans-
ferases (2onz). Hydrogen-bonded sulfonyl groups are pro-
minent in cocrystal structures of matrix metalloproteinases
(e.g., 3ehx).
Onefurtheraspectofhydrogenbondsrequirestheattention
of the designer. Hydrogen bonds are rarely isolated interac-
tions but are strongly influenced by additional polar atoms in
the vicinity. Hydrogen bonds can mutually reinforce each
other in networks. This is observed for aligned hydrogen
bonds in protein secondary structures.
102 Calculations on
biotin-boundstreptavidin indicatethatcooperative hydrogen
bonding may be one source of the particular strength of this
complex.
103 Ring-shaped water clusters owe their stability to
cooperative binding.
72 The stacking of multiple β strands in
amyloid fibrils has been, in part, ascribed to cooperative
hydrogen bonding
104 in a way reminiscent of the association
of urea molecules in nonpolar solvents.
105 Also, one should
consider that branched hydrogen bonds are common in
protein-ligand interfaces.
106 Hydrogen bonds with subopti-
mal geometries may be stabilized by additional partners that
help to satisfy the total hydrogen bonding potential. Before
labeling a particular interaction as “weak” because of its
geometry, one should therefore assess its environment. It will
be important to learn to recognize and to prospectively apply
more complex hydrogen bonding patterns
107 that can be
derivedfromcrystalstructureanalysis.Inthisrespect,materi-
alsscienceandsupramolecularchemistrycanfertilizethearea
ofstructure-baseddrugdesign,forexample,throughtoolslike
the Cambridge Crystallographic Data Center’s Mercury.
108
Neighboring acceptor and donor groups can also weaken
hydrogen bonds. Originally formulated by Jorgensen,
109 the
“secondary electrostatics hypothesis” was soon confirmed
by Zimmerman
110 and is now widely accepted. Hydrogen
Table 1. Hydrogen Bond Acceptor Strengths (pKBHX Scale) and
Frequencies Observed in the CSD for Selected Hydrogen Bonds Types
typical acceptor
strength (pKBHX)
frequency of hydrogen
bond to OH [%]
Acyclic Oxygen Acceptors
amide 2.2-2.6 48
ketone 1.1-1.2 39
sulfone 1.1 37
sulfonamide 1.0 30
ether 1.0-1.2 16
Planar Heterocycles
N-alkylated
imidazole N
2.72 41
pyridine N 1.86 32
oxazole N 1.67 30
pyrazine N 0.92 25
furane O -0.4 0.5
Figure 6. Closest interactions (distances in A ˚ ) formed by the
sulfonyl oxygen atoms of a cathepsin S ligand within the active site
(PDB code 2fra). Most side chains have been omitted for clarity.5068 Journal of Medicinal Chemistry, 2010, Vol. 53, No. 14 Bissantz et al.
bonds to model peptides in the extended (C5) conformer are
weakened by the proximity of the neighboring carbonyl
oxygen to the NH donor.
111
While the hydrogen bond distances of salt bridges are
shorterthanthosebetweenneutralmotifs,indicatingstronger
interactions, this does not necessarily translate into more
favorable binding free energies. The contribution of charge-
assisted protein-ligand hydrogen bonds to binding depends
critically on the protein environment. Theoretical and experi-
mental studies of solvent-exposed salt bridges reveallittlefree
energy gain for the pairing of monovalent ions.
112 We are not
aware of any example in which the formation of charge-
assisted hydrogen bonds on the surface of the binding site of
a complex has led to significant affinity improvements. This
can be rationalized with the high solvation free energy of
solvent exposed charged protein residues, which needs to be
compensatedbyligandbinding.Incontrast,anumberofSAR
examples exists in which charge-assisted hydrogen bonds are
crucial binding hot spots. Common to these is that the
interacting protein motif is at least partially buried and held
in position by other interactions to surrounding residues. A
textbookexample is thecriticalsalt bridgebetweenAsp189at
the bottom of the S1 pocket of trypsin-like serine proteases
with benzamidine inhibitors, where removal of the amidine
groupor reductionofbasicitystronglyreducesactivity.More
recently, it was found that the introduction of a 2-amino
group in lin-benzoguanine as a ligand of tRNA-guanine
transglycosylase leads to a 50-fold lower Ki.
113 The modified
ligand forms acooperativecharge-assistedhydrogen bonding
network involving a part of the protein backbone and a more
remote glutamate side chain (PDB code 2z7k). In a series of
zanamivir analogues binding to neuraminidase, it was found
that a positively charged amino group was roughly 30-fold
more active than a neutral hydroxyl substituent.
114 This
substituent bridges two Glu and Asp side chains with formal
negative charges providing additional electrostatic stabiliza-
tion (PDB code 1bji). Because of the long-range character
of charged interactions, not only the direct protein-ligand
contacts but also the influence of more distant protein
charges should be considered when designing charge-assisted
hydrogen bonds.
WeakHydrogenBonds.Duringrecentyears,anincreasing
amountofattentionhasbeenpaidtoweakerhydrogenbond
interactions.Thisincreasedattentionisadoubleedgesword:
It sharpens the eye for interactions that previously went
unnoticed,butitalsoincreasestheriskofoverinterpretation.
Numerousaccountsofweakhydrogenbondsfallinthelatter
category,
115,116 as they try to ascribe molecular recogni-
tion to selected observed interactions. Nevertheless, weak
hydrogen bonds often do contribute to protein-ligand
binding in a subtly directional fashion, and it is important
to understand that they are, at the very least, not repulsive.
The nature of weak hydrogen bonds has been extensively
analyzed and reviewed by Desiraju.
106,117 Here we will only
briefly discuss the nature of a few representative cases.
Aromatic rings can act as acceptors of hydrogen bonds.
Tsuzuki et al. have calculated the gas phase interaction
between benzene and ammonia to be 2.2 kcal/mol, only
slightly more attractive than that between benzene and
methane (1.5 kcal/mol).
118 In the most stable orientation,
one NH vector is oriented perpendicularly to the ring plane
atthebenzeneringcenter.Likewise,2-pyridoneandbenzene
adopt a T-shaped NH333π hydrogen-bonded arrangement
according to calculations and spectroscopic analysis of the
supersonic-jet-cooled dimer.
119 In proteins, interactions be-
tween NH donors and aromatic side chains are observed
rarely and usually at long distances (>3.5 A ˚ ). Clearly, an
aromatic ring can only be a “reserve” acceptor for a strong
donor. Tyr, Phe, and in particular Trp side chains interact
more frequently with polarized CH groups as donors.
120,121
There are few clear-cut cases where ligand phenyl rings
accept hydrogen bonds from protein amide NH groups,
and it is unlikely that these interactions are the root cause
of affinity gains. Figure 7 shows two examples with reported
NH333π contacts. Addition of a substituted phenyl ring to a
weak Chk1 kinase ligand (Figure 7a) increased affinity from
from 8.5 to 0.026 μM.
122 The additional phenyl ring forms
multiple interactions, including a contact to a valine side
chain, and displaces several water molecules. One of these
had been coordinated to the backbone NH below. Another
NH333π interaction reported for a PDE10 complex
123
structure in reality does not exist: The glutamine side chain
forms two classical hydrogen bonds to water and a tyrosine
andthusfullysatisfiesthehydrogenbondingpotentialofthe
NH2 unit (Figure 7b). While CSD statistics clearly indicate a
preference of aromatic CH groups to be oriented above
phenyl ring planes, there is no such preference for NH and
OH groups. Figure 8 shows radial density plots of the
distance above the aromatic plane of query hydrogen atoms
versus their distance from the centroid in the plane (centroid
shift). These two coordinates project the three-dimensional
distributionofqueryatomsaroundthephenylringontotwo
dimensions with the centroid as the origin, facilitating visual
inspection (details on the query setup and calculation of the
radial distribution plots are found in Materials and Meth-
ods). Hydrogen atoms in XCH units polarized by neighbor-
ing heteroatoms (X = O, N) have a clear preference for
interactions above the ring plane, whereas NH and OH
groups rarely undergo π hydrogen bonds. The NH333π
interaction itself might be stronger than the CH333π inter-
action, but this energy gain is overcompensated by a higher
desolvation cost, since a strong donor will form significantly
better interactions with a stronger acceptor than with a
phenyl ring.
Interactions between CF and polar hydrogen atoms HX
(whereX=O,N)frequentlyoccurinthePDBandCSD,even
if such interactions cannot be classified as strong hydrogen
Figure 7. Structures referred to as NH333π interactions in the
literature. (a) Chk1 kinase ligands. The orange structure has a Ki
of 8.5 μM (PDB code 2c3l), and the green structure has a Ki of
0.026 μM (PDB code 2c3k).
122 The additional phenyl ring displaces
several water molecules, one of which was coordinated to the
backbone NH below. The shortest NH333phenyl distance in the
green structure is 3.4 A ˚ . (b) A PDE10 complex structure with a
reported NH333π contact
123 where in reality the glutamine side
chain forms two classical hydrogen bonds to water and a tyrosine.
Distances are in A ˚ .Perspective Journal of Medicinal Chemistry, 2010, Vol. 53, No. 14 5069
bonds.
124 We have observed a thrombin inhibitor to change
its binding mode upon fluorination of an aryl ring, such that
aC F333HN interaction is formed.
125 In another study on
factor VIIa inhibitors, a fluorinated phenyl ring was shown
to act as an isostere of a pyridine.
126 An increase of affinity
from 455 to 68 nM was observed in sitagliptin analogues
binding to DPP-IV when going from 3,4-difluorinated to
2,4,5-trifluorinated triazolopiperazines.
127 The additional
ortho-F forms interactions at 3.2 A ˚ distance with NH2
groups of Asn and Arg side chains (PDB code 1x70).
The weaker a hydrogen bond donor, the longer is the
hydrogen bond distance and the broader is the distribu-
tion of the observed distances in crystallographic databases.
This is illustrated in Figure 9 for the donor series OH, NH,
acetylene CH, and CH in six-membered aromatic rings. The
larger variation in median distances should not be over-
looked in analyzing and designing structures. The most
prominent weak donor is the CH group. In particular in
kinase inhibitors, C-H333O interactions are frequently
observed.
128 They play an equally important role in stabiliz-
ing planar conformations of linked heterocyclic systems. A
teamatVertexworkingonGSK3inhibitorshaspublishedan
instructive study on the interplay between steric repulsion
and classical and weak hydrogen bonds.
129 Often, CH
groups bound to N or O atoms in aromatic heterocycles
act as donors. The CR-H unit of proteins is also a weak
donor. Calculations indicate that CR-H333OdC interac-
tions are about one-half the strength of an NH333OdC
hydrogen bond.
130 Analysis of peptide X-ray structures
show that the CR-H unit can substitute for stronger do-
nors.
131 A close CR-H333F interaction has been observed in
a thrombin-ligand complex where the introduction of the
fluorine atom led to a 5-fold affinity increase.
132 Finally,
cation-π interactions, discussed further below, might be
regarded as hydrogen-bonded systems, since it is often not
the cationic center itself, but an electron-deficient alkyl
substituent, that forms the direct contact. Protonated histi-
dines can also act as strong CH donors.
133
Halogen Bonds. In an analysis of crystal structure data
published in 1986, Ramasubbu et al. concluded that “the
halogen X in a C-X bond is capable of significant interac-
tions with electrophiles, nucleophiles, and other halogens.
The electrophiles approach X of the C-X “side on”, nearly
normal to C-X, and the nucleophiles nearly “head-on” and
behind the C-X bond.”
134 This observation, valid for the
halogens Cl, Br, and I, is an ideal introduction to the
following two sections on halogen bonds and multipolar
interactions.
In contrast to fluorine, the heavier halogens have unique
electronic properties when bound to aryl or electron with-
drawing alkyl groups. They show an anisotropy of electron
density distribution with a positive area (σ-hole) of electro-
static potential opposite the C-X bond.
135 In a molecular
orbital framework, the origin of the σ hole can be explained
fromthefactthatthethreepairsofunsharedelectronsfollow
an approximate s
2p
2p
2 configuration forming a belt of
negative charge around its central region, whereas the third
p orbital along the C-X axis is distorted toward carbon,
forming the C-X single bond. This leads to attractive
interactions between C-X moieties and carbonyl groups
or other classical H-bond acceptors, with a preference for
linear C-X333B arrangements. For example, distances be-
low van der Waals radius (3.3 A ˚ ) between carbon-bound
chlorine andsp
2-hybridized oxygenalmost exclusively occur
with linear C-Cl333Og e o m e t r i e s .
136 The strength of halogen
bondsincreaseswiththesizeofthehalogenatom.Because
of its mostly electrostatic nature, it also depends on the
electronegativity of the carbon substituents in the
C-X partner and on the electron density of the binding
partner.
137,138 Halogen bonds are significantly weaker
thanhydrogenbonds.Abinitiocalculationsonformaldehyde-
halobenzene dimers give gas phase interaction energies
Figure 8. Radial distribution of hydrogen atoms around a phenyl ring (CSD statistics): (a) hydrogen bound to sp
2 carbon flanked by one or
two heteroatoms (N, O); (b) hydrogen bound to O or N. Queries were set up as described in Materials and Methods. The phenyl ring in (a) is
drawnroughly toscale andshouldserveasaninterpretation aidfor thein-plane (s)andabove-plane distances(h).Darkergraycorresponds to
higher density; peaks above a numerical value of 70 are colored red.
Figure 9. Box plots of hydrogen bond length distributions for the
interaction between weak and strong donors and amide carbonyl
o x y g e na sa c c e p t o r( C S Ds t a t i s t i c s ) .A ni n c r e a s ei nm e d i a nh y d r o g e n
bond length and in breadth of the distribution is observed for
decreasing donor strength.5070 Journal of Medicinal Chemistry, 2010, Vol. 53, No. 14 Bissantz et al.
below 2.5 kcal/mol, corresponding to the strength of
CH333O hydrogen bonds.
139 This is in accord with observa-
tions that halogen bonds involving iodine can displace less
conventional hydrogen bond donors such as the C-H imine
moiety.
140 QM/MM calculations on ligand-enzyme com-
plexes
141 cannot be expected to give meaningful values
because halogen substituents typically form multiple inter-
actions besides a halogen bond and because desolvation
effects are not accounted for.
A large amount of structural and SAR data proves the
existenceofhalogenbondsbothinsmallmoleculecomplexes
and in protein-ligand complexes.
142,143 Typically, replace-
ment of hydrogen by iodine leads to the largest affinity
differences. A 200-fold affinity gain from H to I has been
observed in a series of adenosine kinase inhibitors
144 (PDB
code1lij),whereasClonlyledtoa34-foldaffinityincrease.A
100-fold increase in binding affinity was observed in a class
ofHDM2inhibitors.Figure10showsthattheclosestcontact
between iodine and protein is formed by a carbonyl oxygen,
whereas other van der Waals contacts are significantly longer.
Note that iodine could be replaced by an acetylene sub-
stituent, leading to 4-fold lower affinity.
145 Acetylene and
iodinesubstituentsarecomparableinlength,andtheaffinity
data suggest again that a halogen bond to iodine is compar-
ableinstrengthtoaweakhydrogenbond.A300-foldaffinity
difference upon iodine substitution was observed in a series
of HIV RT inhibitors.
146 In this series, the carbonyl oxygen
ofTyr188formsahalogenbondwithaniodinesubsituent.In
a high resolution structure, this carbonyl oxygen is observed
to bend slightly toward the iodine, although not enough
to abolish a β-sheet hydrogen bond with the Tyr181
nitrogen.
147 In the PDB it is not uncommon to find carbonyl
groups forming both a halogen bond and a hydrogen bond.
Calculations on model systems indicate that energies of
halogen bonds to amide carbonyl groups are largely inde-
pendent from simultaneously formed hydrogen bonds.
148
Affinity gains by iodine substitution drop with longer I333O
distances, as observed, for example, in a series of BACE
inhibitors
149 (PDB code 2iqg), where the affinity gain was
only 25-fold.
In spite of the fact that halogen bonds formed by chlorine
areusuallymuchweaker,theycanplayauniqueroleinsome
complexes.Thebroadspectrumbactericidetriclosaninhibits
the FabI (enoyl reductase) component of bacterial fatty acid
synthesis.
150 Complex structures with several enoyl reduc-
tases have been solved, and all show the same binding mode
of triclosan. One chlorine is situated at the outer rim of the
active site and interacts almost linearly at a distance of
3.3-3.5 A ˚ with a backbone CdO. Strikingly, an extensive
syntheticprogramdirectedatreplacingthischlorineatomby
both lipophilic and hydrogen bonding substituents did not
leadtocompoundswithhigherpotencyagainstP.falciparum
enoyl reductase.
151
We conclude that halogen bonds are weak but specific
interactions that can lead to clear gains in binding affinity.
They belong to the arsenal of structure-based design tools
just like weak hydrogen bonds and, like these, have the
advantage that they are associated with a lower desolvation
cost than classical hydrogen bonds.
Orthogonal Multipolar Interactions. This particular inter-
action motif, characterized by a close orthogonal contact
between two dipolar functional groups, has only recently
received detailed attention.
152 Note that in a completely
orthogonal arrangement between two dipoles, the actual
dipole contribution to interaction energy is zero such that
higher order electrostatic and dispersion terms must be
responsible for the attractiveness of the interaction. The
disappearance of the dipole term may turn a repulsive
electrostatic interaction into an attractive one. Manas et al.
provide an instructive example involving a nitrile interacting
with divalent sulfur.
153
Fluorine substituents are sometimes found at short dis-
tances (3.0-3.7 A ˚ ) and orthogonal to carbonyl carbon
atoms. This arrangement is not the most frequent fluorine
interaction observed in the PDB.
154 Investigations of a
model system in chemical double mutant cycles confirmed
theweaklyattractivenatureoftheorthogonalC-F333CdO
interaction, with a contribution in binding free enthalpy
in apolar environments of ΔΔG=-0.2 to -0.3 kcal/mol.
Multiple SAR examples have shown that increases in bind-
ing affinity can be obtained when this interaction is pre-
sent.
155 Elastase is known to bind peptidic inhibitors with
trifluoracetyl groups much more strongly than those con-
taining acetyl groups,
156 and the corresponding X-ray struc-
tures feature three orthogonal CF333CdO contacts.
157 A
similar effect has been observed in the SAR of abl kinase
inhibitors. In the active site pocket, the CF3 group of
nilotinib forms one interaction orthogonal to an amide
besides two further contacts to the imidazole NH of a
histidine as well as an isoleucine side chain
158 (Figure 11a).
The CF3 derivative is over 5-fold more active than the
corresponding methyl derivative in an autophosphorylation
assay.
159 Many classes of p38 MAP kinase inhibitors typi-
callycontainaphenylringinthelipophilicbackpocketofthe
ATP binding site situated behind the gatekeeper residue.
125
A Merck team working on kinesin spindle protein
160 reports
a dramatic boost in affinity upon fluorine substitution
(Figure 11b), again with one of the two fluorine atoms
interacting orthogonally with an amide bond. It should
not be assumed that this increase in binding free energy
can be ascribed to the interactions formed by fluorine only.
Figure 10. Iodine bond to a backbone carbonyl group in a HDM2
p53 domain crystal structure
145 (PDB code 1t4e, distances in A ˚ ).Perspective Journal of Medicinal Chemistry, 2010, Vol. 53, No. 14 5071
Large components might be due to changes in residual
mobility and desolvation. Still, the examples show the value of
fluorine scans and in particular its targeted use in “fluorophilic”
pockets.
Since halogens can interact both withthe oxygenand with
the carbon atoms of carbonyl groups, forming halogen
bonds and multipolar interactions, respectively, it is instruc-
tivetolookattherelativepropensitiesofbothinteractionsin
the same context. Figure 12 shows results of CSD searches
between carbonyl groups and halogens, where either the
halogen-carbon or the halogen-oxygen distance is below
vanderWaalscontact.Fluorinedoesnothaveanorientation
Figure 11. (a) Fluorine interactions in the complex between nilotinib and abl kinase (PDB code 3cs9).
159 (b) Kinesin spindle protein structure
(2fl6) and activity data of two closely related inhibitor structures.
160Distances are in A ˚ .
Figure 12. OccurrenceofclosecontactsbetweenF(left)andCl(right)atomsandcarbonylgroupsintheCSD.Scatterplotsshowtwodifferent
angledistributions.PointsarecategorizedbytheirdistancetothecarbonandoxygenatomsoftheCdOunit:(b)closecontactbetweenhalogen
andcarbonylC(<3.3A ˚ forF,<3.5A ˚ forCl);(O)closecontactbetweenhalogenandcarbonylO(<3.1A ˚ forF,<3.3A ˚ forCl);(þ)bothclose
contact criteria satisfied.5072 Journal of Medicinal Chemistry, 2010, Vol. 53, No. 14 Bissantz et al.
preference, and the distinction between close contacts to
carbonyl C and O seems somewhat arbitrary. CF bonds
approach carbonyl centers from any direction. For Cl, the
scatterplotdividesintotwodistinctdistributionsforhalogen
bonds and multipolar interactions. Both types of contacts
occur roughly with the same frequency. Chlorine does form
multipolar interactions with carbonyl groups as fluorine
does but shows a tendency for the C-Cl bond to be parallel
rather than orthogonal to the amide plane, a consequence of
theanisotropicdistributionofelectrondensityaroundtheCl
atom. For clarity, Figure 13 shows the two preferred orien-
tations of C-Cl vectors with respect to carbonyl groups. We
haverepeatedthesesearchesforbromineandiodineandfind
qualitatively similar distributions as for chlorine, with an
increasing shift toward more halogen bonds and fewer side-
on interactions. Analogous distributions extracted from the
PDB are so much more scattered that a clear orientation
pattern is not recognizable anymore (data not shown).
HalogensandAromaticRings.Variousgroupshaveanaly-
zed crystallographic data on interactions between aromatic
rings and halogen substituents, arriving at partially contra-
dictoryconclusions.OnthebasisofCSDsearches,Schneider
et al. observe a preference for CH333halogen interactions
but often with significant van der Waals contacts to the
π system, and they do not explicitly distinguish between
fluorineandtheheavierhalogens.
161AsimilarCSDstudyby
Prasanna and Guru Row even concludes that the propensity
fortheformationofCX333πinteractionsishigherinthecase
of fluorine than other halogens,
162 in stark contrast to a
study of fluorine interactions in the PDB.
154 Yet another
study focused exclusively on interactions between fluorine
and hydrogen bond donors, including very weak ones.
163
More recently, the attractive nature of interactions between
heavier halogen substituents and aromatic rings has been
emphasized,inparticularinthecontextofserineproteases
164
andreviews onhalogen bonding.
143Unfortunately,thecited
studies are not suitable to derive a clear picture of the
orientation preferences and interaction energies of halogens
around aromatic rings, since they suffer from one or more
technical deficiencies: a focus on one type of interaction
instead of a consideration of the relative importance of all
alternatives, the lack of differentiation between different
moieties (e.g., halogen bound to aliphatic vs aromatic
carbon), and the analysis of database searches by means of
uncorrected one-dimensional frequency diagrams or scatter
plots instead of probability densities.
ThequeryresultsdepictedinFigure14giveamoreholistic
picture.TheradialdistributionplotsofbothFandClhavein
common that the probability density reaches a maximum in
the plane of the aryl ring, peaking at a centroid-to-halogen
Figure 13. Preferred interaction geometries between chlorine and
carbonyl groups derived from the CSD queries in Figure 12.
Figure 14. Radial distribution of fluorine atoms (top) and chlorine atoms (bottom) around phenyl rings (CSD statistics). Darker gray
correspondstohigherdensity;peaksaboveanumericalvalueof90arecoloredred.Scatterplotsofallhitsforfluorineandchlorine(right-hand
side) are colored by the angle between the phenyl plane and the C-X vector from blue (0, in plane) to green (90, orthogonal).Perspective Journal of Medicinal Chemistry, 2010, Vol. 53, No. 14 5073
distance of 4.6-4.8 A ˚ for F and of 4.9-5.2 A ˚ for Cl. Thus,
bothClandFprefer,byawidemargin,interactionswithCH
over those with the π system. Gas phase calculations
165 and
analyses of PDB structures
154 confirm this trend. Desiraju
classifies CH333halogen interactions as “very weak” hydro-
gen bonds.
166 In a crystallographic study of fluorinated
benzenes, he observed H333F contacts below van der Waals
distance (∼2.6 A ˚ ) with increased fluorine content of the aryl
ring, i.e., with increased hydrogen acidity. Also, short dis-
tances were only observed when CH333F angles approach
linearity. In our larger data set we observe this trend as
well: Distances below ∼2.6 A ˚ are only observed with
CH333Fanglesabove120(FigureS-3),indicativeofaweak
hydrogen bond character of this interaction.
Figure 14 (right-hand side) also shows scatter plots of the
individual occurrences of halogen333phenyl interactions,
coloredbytheanglebetweentheC-Xvectorandthenormal
to the aromatic plane. The hydrogen bond interactions do
notshowadependenceontheorientationoftheC-Xvector.
There is, however, a clear trend for the C-Cl vector to be
perpendicular to the aromatic plane at the closest observed
distances from the centroid (3.2-3.4 A ˚ ) and directly above
the plane. This coincides with a minor second maximum in
the distribution function of Cl. Thus, a minor fraction of Cl
atoms do form a halogen bond-like interaction with phenyl
rings, with the σ-hole facing the π system. This trend is
slightly more pronounced for Br, again with a peak clearly
below van der Waals radius at 3.5 A ˚ (Figure S-6). Note that
the searches in Figure 14 included halogen atoms bound to
sp
3 carbon only. Supporting Information Figures S-4 to S-6
give an overview of all halogen interactions with phenyl
rings, including halogens bound to aromatic rings. The
difference in distribution between halogens boundto alipha-
tic and aromatic carbon clearly indicates that the driving
force for the larger fraction of halogens situated above the
ring plane is the stacking interaction between the two aryl
rings and not the halogen interaction itself. Overall, the
picture emerges that the orthogonal interaction between
the heavier halogens and aromatic rings is attractive, as also
confirmed by quantum chemical calculations in the gas
phase,
164,167 but that its energetic contribution to ligand
binding in water has been overrated because of the high
binding affinity gains observed with ligands containing
chlorinated aromatic moieties as factor Xa and thrombin
inhibitors. Depending on the nature of the ligand, the
difference between a methyl group and Cl at the bottom of
the S1 pocket can vary between 6-fold
168,169 and 10-fold.
164
Desolvationeffectsareanunlikelycauseofthisdifference.
169
However, the chlorine and methyl substituents form a signi-
ficantnumberofadditionalcontactsbesidesinteractingwith
thetyrosinesidechainthatneedtobetakenintoaccountina
fullanalysis.Inparticularforthrombin,theclosestcontactis
often the formation of a halogen bond with a main chain
carbonylgroup(see,forexample,PDBentries1ta6and2jh5)
and not with the tyrosine phenyl ring. Finally, chemical
double mutant experiments in CDCl3 gave repulsive values
for all three halogens Br, Cl, and F interacting with the
π faces of a phenyl ring. Fluorine had the most pronounced
repulsive effect of about 0.7 kcal/mol.
170 These results are
consistent with the crystallographic data and the use of a
solvent less polar than water.
The above analysis of various halogen interactions high-
lights the fact that halogen atoms are not merely lipophilic
appendagestofillhydrophobiccavities.Indesigningligands,
we should be more aware of the detailed nature of lipophilic
pockets to optimally exploit the weak directional nature of
halogen interactions. The typical “good” halogen environ-
ment consists of multiple C-H333X contacts. The more
polarized (acidic) these groups are, the stronger the interact-
ionis,uptothepointwheredesolvationeffectsstarttohavea
detrimental effect. Because of its high electron density and
low polarizability, fluorine prefers dipolar interactions more
strongly than the other halogens.
171 The difference between
typical fluorophilic and fluorophobic environments has
become particularly apparent in a study on neprilysin inhi-
bitors bythe Diederich group.
172 Any fluorine substituent at
a phenyl ring in the S10 pocket led to a decrease in affinity,
a result explained by electrostatically unfavorable close
contacts of organic fluorine with the negatively polarized
π-surfaces of surrounding aromatic amino acid side chains.
In contrast, fluorination of the benzimidazole moiety of the
ligand led to an increase in binding affinity. This ring system
is located in a plane with three surrounding guanidinium
groups of arginine side chains.
Hydrophobic Interactions. Many studies have shown that
the single best structural parameter correlating with binding
affinity is the amount of hydrophobic surface buried upon
ligand binding. It holds for diverse sets of protein-ligand
complexes,
173 for free energies obtained from ITC measure-
ments,
5andforprotein-proteininteractions.
174Onthebasis
of oil/water partitioning experiments, the magnitude of the
hydrophobic effect was estimated to be around 30 cal/
(mol3A ˚ 2),
175 which is the equivalent of 0.7 kcal/mol or a
3.5-fold increase in binding constant for a methyl group.
Essentially all empirical scoring functions used in docking
and de novo design build on similar relationships, and already
the visualization of matching molecular surfaces can be a
useful tool in design.
This is, of course, a highly simplified view. First, we have
seen above that details of (de)solvation and cooperative
effects govern free energy gains through hydrophobic inter-
actions. Second, optimal filling of a hydrophobic pocket is
oftenachievedlongbeforethevanderWaalslimitisreached.
For synthetic host-guest complexes, it has been empirically
established that optimal binding is observed when the guest
occupies about 55% of the volume of the host.
176 The
Diederich laboratory has investigated a series of plasmepsin
II inhibitors with a wide variety of flexible alkyl chains
binding into an induced lipophilic tunnel and could confirm
the validity of the “55% rule” for this system.
177 These
findings stress the importance of residual flexibility in bind-
ing events. Finally, we have seen above in the discussions on
halogeninteractionsandweakhydrogenbondsthatasimple
distinction between “polar” and “unpolar” groups is not
useful; there is a gray zone of weakly polar and directed
interactions in between.
Particularly large gains in binding free energy of several
kcal/mol per heavy atom can be obtained when a lipophilic
protein pocket is optimally occupied by nonpolar ligand
atoms.
178,179 An instructive example stems from the optimi-
zationofinteractionsintheS1specificitypocketoftheserine
protease DPP-IV which is composed of several hydrophobic
Val, Trp, and Tyr side chains. Substitution of the meta-
phenylhydrogenatombya-CH2Fmoietyresultedina400-
fold increase in binding in a series of aminobenzoquinoliz-
ine inhibitors.
180 Figure 15 illustrates the excellent fit of this
substituent to the asymmetric S1 pocket, with five short
hydrophobic contacts to the surrounding side chain atoms.5074 Journal of Medicinal Chemistry, 2010, Vol. 53, No. 14 Bissantz et al.
The 9-fold difference in Kd between a methyl and a mono-
fluoromethyl group can be attributed to the slightly bigger
volume enabling a tighter fit and the roughly 2-fold higher
interaction strength of fluorine compared to hydrogen. This
example emphasizes the potential rewards that can be gained
from the fine-tuning of hydrophobic shape complementarity.
As pointed out above, a significant amount of the large
affinity gains imparted by hydrophobic interactions in nar-
row pockets is due to poor solvation of the pocket in the
unbound state. Simulations on the hydration structure of
different binding sites suggest that the buried water mole-
cules are very poorly hydrogen-bonded.
42,181 Recent experi-
mental studies on cavity hydration indicate that small,
completely apolar cavities might even be completely empty
rather than occupied by a single water molecule.
50
Aryl-Aryl and Alkyl-Aryl Interactions. Aryl rings de-
serve special consideration in the context of hydrophobic
interactions. Interactions with aryl-containing amino acids
like Trp,Phe, Tyr, andHis areubiquitous in proteins,
182-184
and they often expose their aromatic side chain to the
binding site. The special shape and electronic properties of
aromatic rings, which give rise to large polarizabilities and a
considerable quadrupole moment, result in a set of prefer-
red interaction geometries. For interactions between two
π systems, the T-shaped edge-to-face and the parallel-dis-
placed stacking arrangement are predominant. High-level
quantummechanicalcalculationsofthedimerizationenergy
ofbenzene predict thesetwo arrangements tobeisoenergetic
(De = -2.5 kcal/mol),
185 with an absolute value in good
quantitative agreement with experimental results (De=-1.6
to -2.4 kcal/mol).
186,187 In protein structures, the parallel-
displacedgeometryisfoundsomewhatmore frequentlythan
the T-shaped arrangement.
188
Introduction of substituents or insertion of heteroatoms
into aromatic rings influences the relative propensities for
edge-to-face vs parallel-displaced arrangement. Some guide-
lines for the optimization of aryl interactions of a given
geometry are summarized here, taken mainly from the
comprehensive review of Meyer et al.:
35 Stacking arrange-
ments of an electron-poor and an electron-rich aromatic
ring profit from charge transfer. Stacking between electron-
deficient rings is generally preferred over stacking of electron-
rich ones. The preferred orientation of heteroaromatic rings
is significantly affected by the alignment of positive and
negative partial charges and molecular dipoles. Considera-
tion of the detailed distribution of atomic charges and
molecularelectrostaticpotentialsiswarrantedhere.Theuse-
fulness of electrostatic potential maps for the assessment of
interaction strengths with aryl rings has been pointed out.
189
It should be noted, however, that such maps should not be
interpreted as only reflecting local electron density. Through-
space substituent effects can dominate.
190
The attractiveness of edge-to-face interactions can be
increased when the interacting hydrogen atom is rendered
more acidic, most effectively by introducing strongly electron-
withdrawing substituents in ortho- and/or para-position.
High-level ab initio calculations confirm this trend:
191
The T-shaped interaction between benzene as a donor and
fluorobenzene as the acceptor is ∼0.3 kcal/mol weaker than
that of the benzene dimer. With reverted roles (fluoro-
benzene para-H as the donor), the interaction becomes
∼0.6 kcal/mol stronger relative to the benzene dimer.
Investigations of model systems led to the conclusion
that aliphatic-aromatic and aromatic-aromatic edge-to-
face contacts provide similar levels of stabilization.
192 For
T-shaped aliphatic-aromatic interactions there is computa-
tional and experimental evidence that the interaction energy
increases with increasing acidity of the interacting CH unit.
High-level ab initio calculations of dimer dissociation
energies between benzene and ethane, ethylene, and acetylene,
respectively,yieldaclearcorrelationinwhichthemoreacidic
sp-hybridized acetylene (-2.8 kcal/mol) is about 1 kcal/mol
more tightly bound than the sp
3-hybridized ethane (-1.8 kcal/
mol).
193 Database mining in CSD and PDB for interactions
of phenyl rings with methyl groups provides further support
(Figure 16). While methyl groups connected to another sp
3-
hybridized carbon atom (Figure 16b) show a rather broad
range of interaction geometries, the distribution of methyl
groups bound to electronegative atoms is much more biased
towardedge-to-faceinteractions(Figure16a).Thisbehavior
isqualitativelyreproducedinproteinstructures(Figure16c).
The stronger electrostatic interaction anddirectionality aris-
ing from electron-withdrawing substituents have also been
found by model calculations on fluorinated alcohols.
194
Edge-to-face and π-π stacking interactions are not lim-
ited to (hetero)aromatic rings but can also be exploited with
H-bonding arrays such as guanidinium-carboxylate ion
pairs of Arg and Glu/Asp side chains or with the π faces of
amide bonds. These motifs require hydrogen bonding inter-
actions within the π-plane but are rather apolar and highly
polarizableinaperpendiculardirection.Interactionenergies
of intramolecular amide stacking were found to be compe-
titivewithnearest-neighborhydrogenbondinginIRspectro-
scopic measurements of small model peptides.
195 In our own
searches, we find the typical distance between the amide and
aromatic plane to be in the rather broad range of 3.2-3.7 A ˚ .
Several SAR examples from medicinal chemistry pro-
grams illustrate the points made above. The S4 binding
pocket of the serine protease factor Xa is composed of the
Figure 15. X-ray complex crystal structure of human DPP-IV with
an aminobenzoquinolizine inhibitor (R = CH2F) and affinity data
forthreederivatives.
180Theclosesthydrophobicproteincontactsof
the CH2F moiety (distances are less than the sum of van der Waals
radius þ 0.5 A ˚ ) are displayed (PDB code 3kwj).Perspective Journal of Medicinal Chemistry, 2010, Vol. 53, No. 14 5075
side chains of Tyr, Phe, and Trp and provides an “aromatic
box” with opportunities for both edge-to-face and stacking
interactions. The example in Figure 2 above clearly illust-
ratesthestronggainsinbindingaffinitythatcanbeobtained
by filling this pocket. Similarly, in a series of aminothiazole
inhibitors, a more than 300-fold gain in binding affinity
could be achieved by inserting a 3-fluorophenylpyridone
substituentintothispocket.
196Bothligandarylringsinteract
with the surrounding aromatic side chains. In the same
target, a more than 60-fold lower IC50 value could be
obtained by introducing a carbonyl group adjacent to the
nitrogen atom of a morpholine ring.
168 As illustrated in
Figure 17, the additional CdO motif does not interact
directly with the protein but exerts its beneficial effect
through polarization of the ring CH2 on top of Trp
(C-Trp distance: 3.5 A ˚ ), thereby increasing the CH2333π
interaction as well as through conformational preorganiza-
tion of a perpendicular arrangement to the adjacent phenyl
ring. The beneficial effect of acidifying CH groups on top of
an edge-to-face oriented phenyl ring can also be seen in a
series of 2-anilinothiazolone steroid dehydrogenase inhibi-
tors.
197 Introduction of a F-substituent adjacent to two
aromatic CH groups in contact with a Tyr ring increases
binding from IC50=110 nM to IC50=17 nM (PDB code
2rbe).EnhancedvanderWaalscontactsofthefluorineatom
with a neighboring alanine side chain might also contribute.
Finally, a drastic improvement in IC50 for inhibition of p38
MAP kinase was observed when inserting an oxygen atom
between an amide and a methyl group (Figure 18).
198 The
resulting methyl hydroxamate sits on top of a Phe aromatic
ring and interacts additionally with a leucine side chain and
through a weak hydrogen bond with a backbone carbonyl
group. Acidification of the methyl protons through the
attached hydroxamate certainly enhances the interactions
with the Phe ring and the carbonyl acceptor. Similar to
chlorine substituents, acidified CH groups can engage in
both lipophilic and weakly polar interactions.
Figure 16. Radialdistributionofcarbonatoms aroundphenyl rings: (a)CH3 boundtosp
3 C(CSDstatistics); (b) CH3 boundtoO or N(CSD
statistics); (c) CH3 bound to O or N (PDB statistics). Darker gray corresponds to higher density; peaks above a numerical value of 90 are
colored red.
Figure 17. Structure and IC50 values
168 of factor Xa inhibitors
(PDB code 2w26, distances in A ˚ ).5076 Journal of Medicinal Chemistry, 2010, Vol. 53, No. 14 Bissantz et al.
Cation-π Interactions. Cation-π interactions have been
extensively studied in protein structures. Gallivan and
Dougherty found that cation-π interations are rarely
buried
199 and that arginine side chains are more likely to
form such interactions than lysine. Among the aromatic
side chains, tryptophan is featured most prominently.
200
Throughaseriesofmutationstudies,theinteractionstrength
between a buried Trp and a Lys, Arg, or His side chain has
been determined to range from -0.8 to -0.5 kcal/mol.
201
With increasing solvent exposure of the partners, the inter-
action energy dropped significantly. These values are con-
sistent with several earlier studies performed with biological
and synthetic receptor systems (summarized in ref 35). An
instructive example is the complex structure of periplasmic
lysine-, arginine-, and ornithine-binding protein (LAO).
LAO binds lysine and arginine with the same affinity of
about 15 nM.
202 The cationic centers of the amino acids
ligands are sandwiched between the aromatic rings of two
Phe residues at about 3.6 A ˚ distance (PDB codes 1laf and
1lst). In addition, several hydrogen bonds are formed
between the guanidine andammonium groups ofthe ligands
and surrounding residues.
Arginine stacking interactions have rarely been utilized
proactively. Detailed thermodynamic studies of galectinand
lectin ligand complexes have been performed.
203,204 A group
at Vernalis found arginine stacking interactions to be an
important factor in a series of 70 kDa heat shock protein
inhibitors,
205 an example of which has adorned the cover of
this journal in 2009. Arginine stacking plays a role in nucleic
acid binding sites. In particular adenine-arginine pair inter-
actions are conserved within several protein families.
206
The interaction between alkylammonium ions and aromatic
rings can be seen as a special class of alkyl-aryl interaction.
We have seen above that methyl groups favorably interact
with the π face of aromatic rings when bound to an electro-
negative atom. A (formally) positively charged nitrogen is a
particularly strong electronegative substituent, and there-
fore, the direct interaction of an alkylated ammonium group
with an aromatic ring leads to a strongly attractive interac-
tion. Ammonium groups in medicinal chemistry are rarely
permanently charged quaternaryions, sothere is atleast one
proton on the nitrogen atom whose interactions need to be
considered in the design process. Figure S-7 shows examples
illustrating these effects. Carbamoylcholine binds to acetyl-
choline binding protein through a number of short contacts
betweentheN-Megroups andTrp andTyrside chainsinthe
protein. Nicotine forms similar contacts with a different set
of rings (Trp and the lower Tyr residue, contacts not drawn
in Figure S-7a). In addition, the NH group of the nicotine
cation forms a hydrogen bond to a backbone carbonyl
group.
207 The marketed acetylcholinesterase inhibitor done-
pezil binds to its target in a similar fashion, the NH group
being solvated by a structural water molecule.
208 The strong
desolvation component of cationic interactions is high-
lighted particularly well in a recent study on factor Xa
inhibitors by the Diederich group
209 (Figure 19). Stepwise
methylation of an ammonium substituent binding to the S4
pocket increased the binding affinity by 3 orders of magni-
tude.Thisleadstotheconclusionthatthedesolvationcostof
ammoniumNHgroupsbyfaroutweighstheenergygainofa
direct NH33π interaction, even if it is intrinsically attrac-
tive.
210 This is in agreement with studies on a β-hairpin
model, where an enhancement of a cation-π interaction of
about 0.2-0.3 kcal/mol per additional methyl group on a
lysine was found.
211
Figure 18. Effect of a methyl group on the IC50 of a p38 MAP
kinase inhibitor
198 (PDB code 2rg5).
Figure 19. Exampleofcation-πinteractions: afactorXainhibitor scaffoldwithsystematicallyvariedS4pocketsidechains(PDBcode2bok,
distances in A ˚ ).
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Interactions Formed by Sulfur. Divalent sulfur is a highly
versatile atom. It is characterized by the ability to interact
both with electron-poor and with electron-rich functional
groups. Electron-rich ones tend to approach divalent sulfur
along the extension of the C-S bond (σ* direction), while
electron-poor ones tendtoapproachitalong thedirection of
the lone pairs.
212 An example is the pair CdO333SC2, where
the carbonyl oxygen acts as the electron-rich partner. At-
tractive carbonyl-sulfur interactions can have a strong
influence on conformational equilibria.
73
Methionine side chains are both lipophilic and flexible.
Both properties make them good targets in design, for
example, in the binding sites of nuclear hormone recep-
tors.
213 How do methionine side chains interact with aryl
rings? Ab initio calculations have shed some light on the
nature of these interactions. When benzene and either
methanethiol
214 or H2S
215 are used as model systems, the
lowest energy arrangement is that of an SH333π hydrogen
bond, which may serve as a model for cysteine interactions
only.
215Arrangements inwhich thesulfurlone pairspoint at
thearomaticringfaceareavoided.Withdimethylsulfideasa
model system to represent the methionine side chain,
216 the
most stable geometry is one in which the methyl groups
interact with the π system, analogous to the interactions
between methoxy groups and phenyl rings described above.
Direct S333π interactions could not be reproduced.
Methionine333aryl interactions are quite frequent in pro-
tein structures. Pal and Chakrabarti found methionine as
frequentlyasaromaticaminoacidsintheenvironmentofthe
tryptophan indole ring (distance between ring carbon and S
of <4.0 A ˚ ).
217 Out of 1276 methionine residues, 9% were
foundtobeincontactwithanaromaticedgeand8%withan
aromatic face. Imai et al. found that CH333S interactions
accountforthemajorityofallmethioninesulfurinteractions
(∼40%) in the PDB. Close contacts between methionine
sulfur and π systems occurred with a frequency of about
22%,
121includingelectron-poorπsystemssuchasamides.In
the CSD, Zauhar et al. found a pronounced preference for
thioethers to form CH333S interactions in the plane of the
aryl ring.
218Our searches agree with these findings. In fact,
the trend that sulfur atoms of thioethers are preferentially
found in the phenyl ring plane and not above it is also visible
in the corresponding PDB query (Figure S-8). Overall, it
seems that with regard to phenyl ring interactions, divalent
sulfur behaves like a weakly negatively polarized atom not
unlike chlorine.
The binding sites of adenine rings (as part of enzyme
substrates or cofactors) repeatedly feature methionine side
chains. Often, the C-S-C fragment is positioned in a
coplanar fashion above the purine ring at van der Waals
distance (∼4.0 A ˚ ). This arrangement is exemplified by the
complex of catechol-O-methyltransferase with its cofactor
S-adenosylmethionine. The cofactor is sandwiched between
Met 91 and His 142 (Figure 20). The distance between the
sulfuratomandtheclosestringatomis3.6A ˚ .Ithasnotbeen
studied in detail whether this type of arrangement is pre-
defined by the (often highly conserved) adenine binding
pockets or whether it is due to the electronic nature of the
adenine ring system. There is a second common geometric
arrangement between adenine and methionine side chains in
which the terminal methyl group forms the interaction
as found in the ab initio model studies of dimethyl sulfide
and benzene.
216 This geometry is also observed with other
nucleobases, for example, in the complex between herpes
simplex virus type 1 thymidine kinase and thymidine,
219 and
itisconfirmedasthepreferredinteractiongeometrybetween
phenyl rings and sulfur-bound methyl groups in the CSD
(Figure S-8).
Summaryof TypicalInteraction Distances.It isour experi-
encethatsuccessfulinteractivestructure-baseddesignaswell
as a meaningful analysis of experimental or calculated
structures requires an intimate knowledge of the typical
interaction geometries, in particular of the typical distances
involved.Wethereforeconcludebylistingtypicalinteraction
distance ranges in a separate table for reference purposes
(Table 2). It lists distances for specific interactions discussed
in the previous paragraphs, plus distance ranges of several
further frequently occurring interactions. For interactions
involvingaromaticrings,weavoiddistancestocentroidsand
list atom-atom distances instead because these can be readily
measured with most molecular modeling software packages.
Figure 20. Interactionbetweenmethionineandadenineinthecom-
plex between S-adenosylmethionine andcatechol-O-methyltranfer-
ase (PDB code 2cl5, distances in A ˚ ).
Table 2. Summary of Typical Interaction Distances of Selected Non-
covalent Interactions
a
aDistance values are given as the lower and upper 90% percentiles of
the corresponding histogram peak extracted from CSD searches. Inter-
actions are formed with the atoms highlighted in red. In the case of aryl
carbon atoms, the closest distances observed were chosen.5078 Journal of Medicinal Chemistry, 2010, Vol. 53, No. 14 Bissantz et al.
All distance ranges were derived by the same method (see
Materials and Methods) from CSD data.
Conclusions
We have shown how an understanding of typical noncova-
lentprotein-ligandinteractionscanarisefromthesynergistic
useofcrystalstructuredatabasesearching,structures,andas-
sociation properties of biomolecular and synthetic receptor-
ligandsystemsandvariouscomputationalmodels.Awareness
of geometric preferences of a specific interaction enables its
recognition and application in different contexts. Although a
clear decomposition of the energetic contributions of indivi-
dual interactions is, strictly speaking, impossible, approxi-
materelativepropensitiescanbederived.Keepinginmindthe
big picture, i.e., the likelihood of alternative interactions any
particular group can undergo, helps to avoid the mistake of
overemphasizing any particular interaction. In this sense,
there is still a lot to be learned from crystal structure data-
bases. The results of such studies should become textbook
knowledge but could also very well serve as a basis for
improved knowledge-based force fields on the basis of func-
tional groups rather than pairwise atom contacts. Structure-
based design can certainly benefit from neighboring disci-
plines, in particular the analysis of supramolecular synthons
incrystalengineeringandtheinversedesignprocessesapplied
in protein engineering, both of which may foster an increased
understandingoflargerrecurringpatternsbeyondtheconcept
of functional group interactions.
Itisstrikingthatthemultitudeofdifferentinteractiontypes
reviewed here has not yet become part of crystal structure
visualization and molecular design programs. Visualization
oftendoesnotgobeyondtheconceptsofhydrogenbondsand
van der Waals contacts. We have implemented these non-
classical types of interactions in our version of the macro-
molecularcrystalstructuredatabaseandvisualizationsystem,
complemented by a flagging of unfavorable interactions such
as unsatisfied hydrogen bond donors and acceptors in a
lipophilic environment. Most of these options are now avail-
able in the form of PyMol scripts as part of Proasis2.
220
Alreadysuchsimpleenhancementshaveledtoabetterunder-
standing of protein-ligand interactions at play and were well
received by medicinal chemists. In the short term, we see
possibilities for further improvements in a better visual re-
presentation of poorly solvated binding pockets, which offer
potentially large affinity gains. Local dipolar interactions
have been touched upon in this article. Beyond that, helix
dipoles can be very strong but, to our knowledge, have not
been proactively used in the design process. Such secondary
structure elements can, for instance, be visualized in Re-
libaseþ.
47
The increased availability of structural information has led
toagreatamountofdetailedknowledge,butithasalsooverly
focused our attention on “visible interactions”. We need to
becomemoreawareofthefactthatmanyeffectsnotexplicitly
present in a receptor-ligand complex structure (solvation/
desolvation effects, changes in mobility, cooperativity) play a
large and sometimes dominant role. More holisticconceptual
models such as the one proposed by Hunter
87 could increase
the awareness of solvent effects; similar concepts for entropy
might be hard to develop. An increased appreciation of
entropicaspectscanperhapsonlygrowonthebasisofdetailed
investigationsofindividualmodelsystemsandaccuratethermo-
dynamic data. Studies that carefully probe the energetic
contributionsofindividualsubpocketsorligandcomponents,
such as the decomposition of known ligands into fragments,
can provide a significant amount of insight and should
become routine practice in medicinal chemistry.
Finally, as the level of confidence in structure-based design
has increased, it is important to emphasize that any modeled
binding mode remains a model until it is experimentally
validated. Sadly, it has become common practice today to
mingle models and reality. We close with a call for a more
careful assessment of modeled structures. No binding modes
from docking or molecular dynamics calculations should go
unchallenged. The knowledge base for such scrutiny is large
and is waiting for its application.
Materials and Methods
All statistical data on small molecule crystal structures de-
scribed in this article were derived from searches in the CSD,
version 5.30 (November 2008), with the ConQuest 1.11 pro-
gram.
221 Unless noted otherwise, the following general search
flags were set: R factor of e0.10, “3D coordinates determined”,
“not disordered”, “no ions”, “no errors”, “not polymeric”, and
“only organic.” Protein-ligand interactions were analyzed by
extracting binding sites in SD format
222 from Proasis2,
220 a
curated version of the PDB, and generating a separate database
in CSD format with the program PreQuest.
223 Binding sites were
extracted around all HET entries, except metals and commonly
foundsmallions,inthePDB asofDecember 8,2008.Thosewith
less than 5 or more than 100 ligand atoms were removed,
excluding in particular large peptidic ligands. Multiple occur-
rences of the same ligand in one PDB structure were counted as
separate entries. This database contains a total of 77378 binding
sites derived from 25096 PDB entries. Queries were run in
identical manner in the CSD and the PDB ligand database
with one exception: For CSD searches, explicit hydrogen defini-
tions were used, whereas the absence of hydrogen atoms in
the PDB ligands required the use of implicit hydrogen counts
on carbon.
Where preferred interaction distances are quoted in the text,
they were derived in the following manner: Distance histograms
were generated from counts divided by 4πr
2,w h e r er is the
interactiondistance,inordertoaccountfortheincreasingvolume
available at larger distances. Histograms were plotted in 0.05 A ˚
bins. The peaks in the distance histograms were visually located
and characterized by their median and the lower and upper 90%
percentiles (i.e., the range containing 80% of the hits). These are
the range values given in the text and in Table 2. Angle distribu-
tions weretreatedina similar fashion. Angles betweengeometric
objects(atoms,planes)werenormalizedbythe“conecorrection”
(1/sin(angle)).
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To derive frequencies of occurrence of noncovalent interact-
ions, CSD entries containing the interacting fragments exactly
once were compiled. The frequency of occurrence is defined by
Figure 21. Query setup used for searching interactions between
query atoms X and phenyl rings.Perspective Journal of Medicinal Chemistry, 2010, Vol. 53, No. 14 5079
the fraction of entries that form the interaction within the
geometric limits defined earlier.
Maps for interactions between functional groups and phenyl
ringswerecreatedbymeasuring,foraqueryatomX,thedistance
above the phenyl ring plane h and the distance from the centroid
to the query atom r (Figure 21). From these parameters, the
in-plane distance between X and the centroid was calculated
(centroid shift s). A limit of 7 A ˚ was used for the centroid-X
distance.Toavoidspuriousmappingofinteractions“behind”the
phenyl ring, queries were limited to a half sphere by limiting the
angle C-H1-Xt oe90.P l o t so fh vs s effectively project the
space of this half sphere to two dimensions. Radial distribution
plots were generated by counting hits in 0.1 A ˚   0.1 A ˚ distance
bins(hvss)andscaledby1/(2πr
2),whereristhedistancebetween
the centroid and the query atom X. In addition, all bins were
scaled by the total number of counts.
All depictions of chemical structures in this article have been
generated with PyMOL.
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